By Chris Wack

GH Research shares were up 801 to $19.15 after the company said the primary endpoint was met in a Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression.

The Dublin-based biopharmaceutical company said the trial recruited 81 patients with TRD, with 40 patients receiving GH001 and 41 receiving placebo.

Psychotherapeutic intervention wasn't a component of either part of this trial, said the company.

GH said GH001 led to a significant reduction of patients on the Montgomery-Asberg Depression Rating Scale compared with the placebo group.

All secondary endpoints in the trial were met, with results consistent with the primary endpoint, the company said.

GH001 was well-tolerated and no serious adverse events were reported in the double-blind part of the trial, and all treatment emergent adverse events were mild or moderate with no severe adverse events observed, said GH. There was no evidence of treatment-emergent suicidal ideation or behavior after treatment with GH001, the company said.

As of Jan. 22, nine patients are ongoing, 54 patients have completed and 18 patients have discontinued early, added GH.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

February 03, 2025 09:58 ET (14:58 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.